Breast cancer demonstrates extensive heterogeneity at both inter- and intra-tumoral levels, driven by distinct genomic, epigenomic, transcriptomic, and proteomic variations that contribute to differential therapeutic responses and disease progression
The half-lives vary significantly: BPC-157 appears to have a relatively short plasma half-life (under 4 hours in rodent studies) but demonstrates prolonged tissue effects, TB-500 has a longer half-life of approximately 24 days, and GHK-Cu's pharmacokinetics show rapid clearance but sustained signaling effects in treated tissue
Vegetrinusok s vegnok szmra is alkalmas termk Mnuszok Nincsenek
Ajani JA, D'Amico TA, Bentrem DJ, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Farjah F, Gerdes H, Gibson M, Grierson P, Hofstetter WL , IIson DH, Jalal S, Keswani RN, Kim S, Kleinberg LR, Klempner S, Lacy J, Licciardi F, Ly QP, Matkowskyj KA, McNamara M, Miller A, MukherjeeS, Mulcahy MF, Outlaw D, Perry KA, Pimiento J, Poultsides GA, Reznik S, Roses RE, Strong VE, Su S, Wang HL, Wiesner G, Willett CG, Yakoub D, Yoon H, McMillian NR, Pluchino LA
